HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Gliclazide

HCID 178844217
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
1185039-30-8
Standard SMILES
Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1
InChIKey
BOVGTQGAOIONJV-UHFFFAOYSA-N
Molecular formula
C15H21N3O3S
Average molar mass
323.4 g/mol

Overview

Gliclazide is a N-sulfonylurea. It has a role as a hypoglycemic agent, a radical scavenger and an insulin secretagogue.

Names & identifiers

Preferred name
Gliclazide
IUPAC
1-(3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-3-(4-methylphenyl)sulfonylurea
English name
Gliclazide-d4
Molecular formula
C15H21N3O3S
Molecular weight
323.41054

Names & synonyms

gliclazide21187-98-4GlimicronGliclazidaDiamicronDTXSID9023095S-852S-17021-(3-Azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea1-(Hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)ureaDTXCID003095CHEBI:31654
Show more names
S-1702-d4Diamicron-d4Gliclazide-dNordialex-d4Glimicron-d4Gliclazide-d4[2H4]-GliclazideGliclazide-D4 (Standard)1-[4-methyl(2,3,5,6-2H?)benzenesulfonyl]-3-{octahydrocyclopenta[c]pyrrol-2-yl}ureaN-[[(Hexahydrocylopenta[c]pyrrol-2(1H)-yl]amino]carbonyl]-4-methyl-(benzene-d4)sulfonamide
NSC-758673J3.151HSE-1702GliclazidumSE 1702GlyclazideGliklazidS 1702

Database identifiers

CAS
1185039-30-8
ChEMBL
CHEMBL427216

Properties

Computed structural propertiesFilling in

XLogP
1.5
Topological polar surface area
86.9 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
4
Rotatable bonds
3
Heavy atoms
22
Formal charge
0
Complexity
497

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals

LogP2.6
Solubility · 2 items

1.90e-01 g/L

42.6 [ug/mL] (The mean of the results at pH 7.4)

Human DrugsOral hypoglycaemic agents
Melting Point · 2 items

180-182

181 °C

Physical DescriptionSolid
Collision Cross Section · 2 items

164.21 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

178 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 77.5% (55 of 71) of all reports.

Warning

H302 (12.7%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P264, P270, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 71 reports by companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 4 (12.7%)

Toxicology

Drug Induced Liver Injury · 5 items

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Gliclazide

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Safety data

Signal word
Danger
Symbol(GHS)
GHS08

Chemistry & industry

Pharmacology

ATC Code · 4 items

A10BB09

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

A10BB09

Protein Binding94%, highly bound to plasma proteins
Pharmacodynamics · 1 item

Based on the pharmacological properties, gliclazide is a second generation sulphonylurea which acts as a hypoglycemic agent. It stimulates β cells of the islet of Langerhans in the pancreas to release insulin. It also enhances peripheral insulin sensitivity. Overall, it potentiates insulin release and improves insulin dynamics.

Mechanism of Action · 1 item

Gliclazide binds to the β cell sulfonyl urea receptor (SUR1). This binding subsequently blocks the ATP sensitive potassium channels. The binding results in closure of the channels and leads to a resulting decrease in potassium efflux leads to depolarization of the β cells. This opens voltage-dependent calcium channels in the β cell resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules.

Biological Half-Life10.4 hours. Duration of action is 10-24 hours.
Metabolism/Metabolites · 2 items

Extensively metabolized in the liver. Less than 1% of the orally administered dose appears unchanged in the urine. Metabolites include oxidized and hydroxylated derivates, as well as glucuronic acid conjugates.

Gliclazide has known human metabolites that include 7-hydroxy-gliclazide, Methylhydroxygliclazide, and 6-hydroxy-gliclazide.

MeSH Pharmacological ClassificationSubstances which lower blood glucose levels.
Absorption, Distribution and Excretion · 2 items

Rapidly and well absorbed but may have wide inter- and intra-individual variability. Peak plasma concentrations occur within 4-6 hours of oral administration.

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
ChEBI
CHEBI:31654
EC Number
244-260-5
Nikkaji
J3.151H
Melting point
180 · 180-182°C
storage temp.
-20 °C · -20°C Freezer
solubility
Chloroform (Slightly), Methanol (Slightly)
form
Solid
color
White to Off-White
Symbol(GHS)
8 · GHS08
Signal word
Danger

Metabolites and conjugates are eliminated primarily by the kidneys (60-70%) and also in the feces (10-20%).

Cellular LocationsExtracellular
Metabolite PathwaysGliclazide Action Pathway

Uses & manufacturing

UsesUse (kg; approx.) in Germany (2009): >10

Applications

UsesA sulfonylurea hypoglycemic agent. Used as an antidiabetic.

UsesAs a sulfonylurea hypoglycemic agent, Gliclazide-d4 can be used as an antidiabetic.